Magnetic brain stimulation for weight gain caused by antipsychotic medicines in schizophrenia
Tests magnetic brain stimulation against sham stimulation for antipsychotic-related weight gain in schizophrenia.
Plain-language title generated from the registry record
Registry title: The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
Key facts
- Where
- Changsha, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 60 with schizophrenia who gained weight (around 7%) after starting antipsychotic medicine within the last 2 years.
- Age
- 18 to 60 years
- Sex
- All sexes
- Disease stage
- Schizophrenia confirmed by the DSM-5 diagnostic criteria (SCID-5 interview), with weight gain of around 7% after taking antipsychotics within 2 years.
- Earlier treatment
- Must be on a stable medicine regimen at enrollment. Cannot have had regular TMS, ECT or weight-loss treatment in the past month.
Main reasons for not taking part
- Another mental illness diagnosed under DSM-5
- Other severe physical diseases
- Active suicidal thoughts
- Alcohol or substance use disorder, now or in the past
- Metal implants or devices in the head, epilepsy history, or other reasons that rule out MRI or deep TMS
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07795554, who can take part
Where in China
- The Second Xiangya Hospital of Central South UniversityChangsha, ChinaContact: KaHei ChanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Xiangya Hospital of Central South University
- Trial code
- NCT07795554
- Record updated
- 27 October 2026
- Original description
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. There are no hitherto effective treatments for reducing antipsychotic-induced weight gain. Recently, research suggest that Accelerated dTMS (a-dTMS) which deliver more than one daily TMS session indicates greater efficacy than other TMS treatment. Symptom provocation is believed to improve the clinical responses to TMS. In this study, the investigators, firstly, evaluate the safety and effectiveness of a-dTMS for reducing antipsychotic-induced weight gain and secondly, to establish a predictive model of therapeutic response and to explore the underlying mechanisms of dTMS for reducing antipsychotic-induced weight gain, based on multimodal radiomics and metabolomics approaches.Read full original descriptionShow less
The Effects of Improving Antipsychotic-induced Weight Gain by Accelerated dTMS After Food Cue-induced Craving, A Double-Blind, Randomized, Sham-Controlled Clinical Trial.
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. There are no hitherto effective treatments for reducing antipsychotic-induced weight gain. Recently, research suggest that Accelerated dTMS (a-dTMS) which deliver more than one daily TMS session indicates greater efficacy than other TMS treatment. Symptom provocation is believed to improve the clinical responses to TMS. In this study, the investigators, firstly, evaluate the safety and effectiveness of a-dTMS for reducing antipsychotic-induced weight gain and secondly, to establish a predictive model of therapeutic response and to explore the underlying mechanisms of dTMS for reducing antipsychotic-induced weight gain, based on multimodal radiomics and metabolomics approaches.
Inclusion: Aged between 18-60; Meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for schizophrenia, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5); Gaining body weight around 7% after intaking antipsychotics within 2 years; Participants were on a stable medication regimen at the time of enrollment. ●Written informed consent was obtained from both the participants and their legally authorized guardians.
Exclusion: Participants who switch antipsychotic drugs (APDs) or require a dose modification exceeding 25% of the baseline dosage during the study period; Receipt of regular transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or weight-loss interventions within the past month; Diagnosed with other mental diseases in accordance with DSM-V; Comorbid with other severe physiological diseases; A history of alcohol or substance use disorder (or abuse); Presence of metal implants or any other conditions contraindicated for magnetic resonance imaging (MRI); Presence of intracranial metal or electronic devices, a personal or family history of epilepsy, or any other standard contraindications to deep transcranial magnetic stimulation; Active suicidal ideation; Pregnant or lactating women.